Menu
Recruiting NCT05007561

Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences

Early Phase I Interventional Naltrexone Placebo

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Naltrexone Hydrochloride, Placebo.
Who it may be relevant to
Registry conditions: Naltrexone, Placebo. Basic parameters: 18 years — 25 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The study is a randomized, placebo-controlled design with the opioid antagonist, oral naltrexone. Following random assignment, participants will take 50mg of naltrexone or placebo once a day for 7 days. On days 1 - 7, participants complete reports of their feelings of social connection and mood in order to assess more naturalistic feelings in response to opportunities for social connection outside of the laboratory setting. Additionally, at the end of each day, they complete a physical symptoms questionnaire. On the 7th day, participants will come to the SDSU MRI scanning facility to complete tasks designed to elicit feelings of social connection in the fMRI scanner. After the scan, feelings in response to the scanner tasks will be collected.

Interventions

  • Drug Naltrexone Hydrochloride
    oral naltrexone
  • Drug Placebo
    oral sugar pill

Primary outcome measures

  • Daily feelings of social connection via ecological momentary assessment [Time frame: post-treatment, change across 7 days]
  • Bold Oxygen-level Dependent (BOLD) Activations in Prespecified ROIs [Time frame: Day 7, approximately 60 mins after taking study drug]
  • feelings in response to neuroimaging tasks [Time frame: Day 7, approximately 150 minutes after taking study drug]
Secondary outcome measures (1)
  • physical symptoms via daily diary [Time frame: end of day on days 1-7]

Eligibility criteria

Inclusion criteria

  • good health
  • English fluency
  • willing to provide contact information for 4-6 close others
  • willing to provide digital photographs of 2 close others
  • own a smartphone

Exclusion criteria

  • presence of medical devices, implants, or other metal objects in or on the body that cannot be removed
  • tattooed eyeliner
  • a body habitus prohibiting MRI scanning
  • claustrophobia
  • self-reported chronic mental or physical illness
  • current and regular use of prescription medication
  • previous history of having difficulty taking pills
  • current use of opioid analgesics
  • depressive symptoms above a 9 on Patient Health Questionnaire
  • excessive alcohol use
  • positive urine drug test
  • body mass index (BMI) greater than 35
  • pregnancy or plans to become pregnant in next 6 months
  • positive urine pregnancy test

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Basic science

Study locations

United States · 1 center
  • San Diego State University — San Diego

Identifiers

NCT: NCT05007561 · HS-2020-0188-SMT · R01DA052883

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗